Brief: Nordic Nanovector: Results Of Preclinical Study Of Betalutin

Thor Medical ASA

08/10/2020 07:09

Oct 8 (Reuters) - Nordic Nanovector ASA  NORN.OL :
    * NORDIC NANOVECTOR PUBLISHES RESULTS OF PRECLINICAL STUDY
DEMONSTRATING BETALUTIN® REVERSES TUMOUR RESISTANCE TO RITUXIMAB
IN NHL DISEASE MODELS
    * BETALUTIN® (AN ANTI-CD37 RADIOIMMUNOCONJUGATE) ACTED
SYNERGISTICALLY WITH RITUXIMAB (ANTI-CD20 IMMUNOTHERAPY) TO
SUPPRESS TUMOUR GROWTH IN A RITUXIMAB-RESISTANT XENOGRAFT NHL
MOUSE MODEL
    * IN NHL CELL LINES, BETALUTIN® WAS FOUND TO SUBSTANTIALLY
INCREASE CD20 EXPRESSION AND RITUXIMAB BINDING TO
RITUXIMAB-RESISTANT RAJI2R CELLS AND TO INCREASE
RITUXIMAB-MEDIATED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
(ADCC) ACTIVITY, RESULTING IN SIGNIFICANT TUMOR GROWTH DELAY

Source text for Eikon:  ID:nWkrWZHds 
Further company coverage:  NORN.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))